EGTX — Egetis Therapeutics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK2.11bn
- SEK1.97bn
- SEK62.40m
Brief: Egetis Therapeutics Q1 Loss Widens To SEK 75.0 Mln
Brief: Egetis Therapeutics Chairman Thomas Lönngren To Decline Re-Election
Brief: Egetis Q4 Loss Widens To SEK 86.3 Mln
Brief: Egetis Therapeutics FY Adjusted EPS SEK -1.3
Brief: Egetis Therapeutics Updates On Status Of ReTRIACt Trial
Brief: Egetis Q3 Loss SEK 86.2 Mln
Brief: Egetis Therapeutics 9M Adjusted EPS SEK -1
Brief: Egetis Therapeutics Resolves On Directed Issues Of Warrants, Convertible Bond
Brief: Egetis Announces EMA Validation For Emcitate
Brief: Egetis Therapeutics Secures Approx. Sek 462 Mln In Combined Financing Comprising
Brief: Egetis Submits Marketing Authorisation Application For Emcitate To EMA
Brief: Egetis Therapeutics H1 Revenue at SEK 12.7 Million
Brief: Egetis Therapeutics Board Director Mats Blom Acquires 200,000 Shares
Brief: Egetis Terminates Discussions Regarding Potential Acquisition, Provides Corporate Update
Brief: Egetis Q1 Loss SEK 74.9 Mln
Brief: Egetis Therapeutics Q1 Adj. EPS at SEK -0.3
Brief: Egetis Comments On M&A Rumors
Brief: Egetis Therapeutics Q4 Loss Widens To SEK 77.8 Mln
Brief: Egetis Therapeutics Carries Out Directed Share Issue Of SEK 210 Million